Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero

Blood (2023) 142 (Supplement 1): 96.

https://doi.org/10.1182/blood-2023-179152

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial

Blood (2023) 142 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2023-173849

Published: 2023

Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Blood (2023) 142 (Supplement 1): 1028.

https://doi.org/10.1182/blood-2023-178933

Published: 2023

Journal Articles

Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews

Paula Rodríguez Otero, Krina K. Patel, Noopur S. Raje, Olga Moshkovich, Heather Gerould, Jennifer Devlen, Devender Dhanda, Laurie Eliason, Mark Cook, Mihaela Popa-McKiver, Salomon Manier

Blood (2023) 142 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2023-173840

Published: 2023

Journal Articles

Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells

Pascal Gelebart, May Eriksen Gjerstad, Susanne Benjaminsen, Jianhua Han, Ida Karlsen, Mireia Mayoral Safont, Calum Leitch, Zinayida Fandalyuk, Mihaela Popa, Lars Helgeland, Bela Papp, Fanny Baran-Marszak, Emmet McCormack

Blood (2023) 142 (17): 1478–1493.

https://doi.org/10.1182/blood.2022015581

Published: 2023

Includes: Supplemental data

Journal Articles

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Tara Helen Dowling Dowling Steinsland, MSc, Stein-Erik Gullaksen, MS, PhD, Geir Bredholt, PhD, Calum Leitch, PhD, Mireia Mayoral Safont, BS, Øystein Bruserud, MD PhD, Mihaela Popa, Astri Maaland, Helen Heyerdahl, PhD, Jostein Dahle, PhD, Bjorn T. Gjertsen, MD PhD, Emmet Mccormack, BSc, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142899

Published: 2020

Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo

Blood (2019) 134 (Supplement_1): 3480.

https://doi.org/10.1182/blood-2019-122232

Published: 2019

Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD

Blood (2019) 134 (Supplement_1): 1853.

https://doi.org/10.1182/blood-2019-128760

Published: 2019

Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2018-99-116225

Published: 2018

Journal Articles

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Sundar Jagannath, MD, Jesus G. Berdeja, MD, Robert M Rifkin, MD, Craig E. Cole, MD, Michael Alan Thompson, MD PhD, Ravi Vij, MBBS, Mihaela Popa-McKiver, PhD, Rao Saleem, Oumar Sy, PhD, William Bensinger, MD

Blood (2018) 132 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2018-99-112077

Published: 2018

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2018-99-112080

Published: 2018

Journal Articles

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

Misbah Sabir, MSc, Monica Hellesoy, PhD, Jarno Kivioja, MSc, Caroline Engen, MD, Claire Amiable, Mihaela Popa, Remi Guillon, Øystein Bruserud, MD PhD, Caroline A Heckman, PhD, Emmet McCormack, BSc, PhD, Dominique Surleraux, Bjørn Tore Gjertsen

Blood (2017) 130 (Supplement 1): 3349.

https://doi.org/10.1182/blood.V130.Suppl_1.3349.3349

Published: 2017

Journal Articles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Blood (2017) 130 (6): 789–802.

https://doi.org/10.1182/blood-2016-02-699363

Published: 2017

Includes: Supplemental data

Journal Articles

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

Stephen Ansell, MD PhD, Martin E Gutierrez, MD, Margaret A. Shipp, MD, Douglas Gladstone, MD, Alison Moskowitz, Ivan Borello, Mihaela Popa-Mckiver, Benedetto Farsaci, Lili Zhu, MS, Alexander M. Lesokhin, MD, Philippe Armand, MD PhD

Blood (2016) 128 (22): 183.

https://doi.org/10.1182/blood.V128.22.183.183

Published: 2016

Journal Articles

Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia

Riikka Karjalainen, Mihaela Popa, Dr, Minxia Liu, Mika Kontro, Mireia Mayoral Safont, Alun Parsons, MSc, Kimmo Porkka, MD PhD, Krister Wennerberg, Emmet McCormack, Dr, PhD, Bjørn T. Gjertsen, Caroline A Heckman, PhD

Blood (2016) 128 (22): 32.

https://doi.org/10.1182/blood.V128.22.32.32

Published: 2016

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Graham P. Collins, MD PhD, Jonathon B. Cohen, MD, Ahmad S. Halwani, MD, Carmelo Carlo-Stella, MD, Michael M. Millenson, MD, Mariano Provencio, MD PhD, Eva Domingo Domenech, MD, Lisa Giulino Roth, MD, Luca Castagna, MD, Kazunobu Kato, MD, Mihaela Popa McKiver, Anne Sumbul, Lili Zhu, MS, Armando Santoro, MD

Blood (2016) 128 (22): 3502.

https://doi.org/10.1182/blood.V128.22.3502.3502

Published: 2016

Journal Articles

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Blood (2008) 112 (11): 4435.

https://doi.org/10.1182/blood.V112.11.4435.4435

Published: 2008

NARROW

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews

Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)

Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only